Temozolomide plus radiotherapy for glioblastoma in a Canadian province: efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation.
about
Current evidence of temozolomide and bevacizumab in treatment of gliomas.Paradoxical prognostic impact of TERT promoter mutations in gliomas depends on different histological and genetic backgrounds.The Clinical Significance of O6-Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis.Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.REST, not REST4, is a risk factor associated with radiotherapy plus chemotherapy efficacy in glioma.
P2860
Temozolomide plus radiotherapy for glioblastoma in a Canadian province: efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Temozolomide plus radiotherapy ...... nsferase promoter methylation.
@en
Temozolomide plus radiotherapy ...... nsferase promoter methylation.
@nl
type
label
Temozolomide plus radiotherapy ...... nsferase promoter methylation.
@en
Temozolomide plus radiotherapy ...... nsferase promoter methylation.
@nl
prefLabel
Temozolomide plus radiotherapy ...... nsferase promoter methylation.
@en
Temozolomide plus radiotherapy ...... nsferase promoter methylation.
@nl
P2860
P356
P1476
Temozolomide plus radiotherapy ...... nsferase promoter methylation.
@en
P2093
Carole R Chambers
Nadine Lam
P2860
P304
P356
10.1177/1078155211426198
P577
2011-11-07T00:00:00Z